drugset / Trial / NCT02296281
Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury
Phase 2
Unknown
48 enrolled
Beijing Continent Pharmaceutical Co, Ltd.
GNI-EPS Pharmaceuticals, Inc. (GNI Group) · collabShanghai Genomics, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to treat grade 2 or above radiation-induced lung injury patients.
Timeline
- Start
- 2015-01
- Primary completion
- 2016-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirfenidone | Small molecule | — | — |